Hi, what are you looking for?
Teva is now close to the 4.6% stake in Mylan that will give it standing in the Netherlands courts.
Mylan has confirmed it will dual list on the TASE and Nasdaq if it acquires Perrigo
Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott...
A Credit Suisse study finds that most hostile bids fail, especially if antitrust concerns are involved.
Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, are pushing Mylan to take Teva’s $40 billion take-over bid offer seriously.
In the three way takeover battle Mylan is getting nervous.
Three Way Takeover Battle: believes their offer will win approval from Perrigo stockholders.
Perrigo Company (NYSE:PRGO; TASE:PRGO) CEO Joseph Papa is ready to talk with Mylan N.V. (MYL) about its takeover bid, but at a higher price....
Teva CFO Eyal Desheh told Merrill Lynch that it could secure antitrust clearance for the takeover in 4-7 months.
As Israeli pharmaceutical giant Teva pushes ahead with a $40-billion dollar hostile bid for US generic drugmaker Mylan, Brent Saunders, CEO of...